<DOC>
	<DOCNO>NCT00522951</DOCNO>
	<brief_summary>This study conduct compare contrast effect safety SH L562BB ProHance , already approve pharmaceutical product similar indication .</brief_summary>
	<brief_title>SH L 562BB Phase II/III Dose Justification Gadoteridol-controlled Comparative Study</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Japanese patient least 20 year age Patients diagnose primary cancer Patients metastatic lesion CT/MRI Patients contraindication MRI examinations Patients severe renal disorder Patients extremely serious general condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>MRI</keyword>
	<keyword>Brain Metastasis</keyword>
	<keyword>Gadolinium</keyword>
	<keyword>Imaging</keyword>
	<keyword>Diagnostic Agent</keyword>
</DOC>